This article is more than 5 years old. Information may no longer be current.

Two formulations of hyaluronic acid fillers effective in treating nasolabial folds in Asians

Two formulations of hyaluronic acid fillers, biphasic nonanimal stabilized hyaluronic acid and monophasic monodensified hyaluronic acid, were effective and safe for treating nasolabial folds in Asians, according to recently published study results.

Researchers in Shanghai, China, conducted a randomized study of 49 patients aged 18 to 65 years with moderate-to-severe nasolabial folds. Twenty-five patients (mean age, 47.7 years) received monophasic monodensified hyaluronic acid (MMHA; 16 mg/mL; cross-linked by divinyl sulfone, Matrifil, Haohai) while 24 patients (mean age, 48 years) received biphasic nonaminal stabilized hyaluronic acid (BHA; 20 mg/mL; Restylane, Galderma). All patients but one were women.

There was touch-up treatment as necessary at 4-week follow-up.

Masked investigators measured effectiveness at 24 weeks, and patients were asked to self-rate their Global Aesthetic Improvement scale score immediately after treatment and at 24 weeks.

Patients in both cohorts achieved satisfactory outcome in nasolabial folds correction, according to significant reductions in the mean Wrinkle Reduction Severity Scale score from week 1 to week 24, when compared with baseline.

To achieve full correction in each patient, an average of 0.69 ± 0.30 mL of product was used in the MMHA cohort and a volume of 0.86 ± 0.23 mL each side for the BHA cohort (P < .01).

Effectiveness at 24 weeks included 84% patients in the MMHA cohort and 70.8% in the BHA cohort who considered their nasolabial folds to be “very much improved or “much improved.” Investigators found 20 patients in the MMHA cohort (84%) and 16 in the BHA cohort (62.5%) to be “much improved or “very much improved.”

Four patients experienced minor adverse events, with two adverse events determined to be potentially treatment-related (one from each group), including redness and itch at hyaluronic acid injection area. There were no serious treatment-related adverse events reported.

“Among the multiple commercialized [hyaluronic acid] products, MMHA and BHA are the two most commonly used formulations,” the researchers wrote. “Both MMHA and BHA are suitable for treating [nasolabial folds] in the Asian population and produce long-lasting and satisfactory results. [MMHA] provides similar patient satisfaction to BHA while requiring less injection volume. Both formulations of [hyaluronic acid] are safe with good biocompatibility.” – by Bruce Thiel

Disclosure: The researchers report no relevant financial disclosures.